JP2024533234A5 - - Google Patents

Info

Publication number
JP2024533234A5
JP2024533234A5 JP2024514484A JP2024514484A JP2024533234A5 JP 2024533234 A5 JP2024533234 A5 JP 2024533234A5 JP 2024514484 A JP2024514484 A JP 2024514484A JP 2024514484 A JP2024514484 A JP 2024514484A JP 2024533234 A5 JP2024533234 A5 JP 2024533234A5
Authority
JP
Japan
Prior art keywords
antibody
seq
nucleic acid
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533234A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/074696 external-priority patent/WO2023031473A1/en
Publication of JP2024533234A publication Critical patent/JP2024533234A/ja
Publication of JP2024533234A5 publication Critical patent/JP2024533234A5/ja
Pending legal-status Critical Current

Links

JP2024514484A 2021-09-06 2022-09-06 Cd27に結合する能力を有する抗体、そのバリアントおよびその使用 Pending JP2024533234A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21195118 2021-09-06
EP21195118.1 2021-09-06
EP22173126.8 2022-05-12
EP22173126 2022-05-12
PCT/EP2022/074696 WO2023031473A1 (en) 2021-09-06 2022-09-06 Antibodies capable of binding to cd27, variants thereof and uses thereof

Publications (2)

Publication Number Publication Date
JP2024533234A JP2024533234A (ja) 2024-09-12
JP2024533234A5 true JP2024533234A5 (cg-RX-API-DMAC7.html) 2025-08-28

Family

ID=83400576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514484A Pending JP2024533234A (ja) 2021-09-06 2022-09-06 Cd27に結合する能力を有する抗体、そのバリアントおよびその使用

Country Status (14)

Country Link
US (4) US20230109496A1 (cg-RX-API-DMAC7.html)
EP (1) EP4399227A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024533234A (cg-RX-API-DMAC7.html)
KR (1) KR20240051280A (cg-RX-API-DMAC7.html)
AR (1) AR127743A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022338208A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231003A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000669A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024003578A2 (cg-RX-API-DMAC7.html)
IL (1) IL311141A (cg-RX-API-DMAC7.html)
MX (1) MX2024002781A (cg-RX-API-DMAC7.html)
PE (1) PE20240883A1 (cg-RX-API-DMAC7.html)
TW (1) TW202328192A (cg-RX-API-DMAC7.html)
WO (1) WO2023031473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3253038A1 (en) * 2022-05-12 2023-11-16 Genmab A/S LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
IL324457A (en) * 2023-05-12 2026-01-01 Genmab As Antibodies capable of binding to ox40, their variants and uses thereof
CN122249464A (zh) * 2023-11-30 2026-06-19 金麦安博股份有限公司 在组合疗法中的能够结合ox40的抗体

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US835A (en) 1838-07-12 X i i i x
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
EP2391343B1 (en) 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
JP6002659B2 (ja) 2010-04-13 2016-10-05 セルデックス・セラピューティクス・インコーポレイテッド ヒトcd27に結合する抗体およびその使用
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CA2804550C (en) 2010-07-09 2021-01-05 Bionovion Holding B.V. Agonistic antibody to cd27
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
MX387324B (es) 2013-01-10 2025-03-18 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
EP3932947A1 (en) 2013-03-14 2022-01-05 Translate Bio MA, Inc. Methods and compositions for delivering mrna coded antibodies
ES2967701T3 (es) 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
JP2017513481A (ja) 2014-04-16 2017-06-01 ユーシービー バイオファルマ エスピーアールエル 多量体Fcタンパク質
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11191849B2 (en) 2016-06-30 2021-12-07 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA
CA3033665A1 (en) * 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
EP3497120A1 (en) 2016-08-12 2019-06-19 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3535291A1 (en) 2016-11-01 2019-09-11 Genmab B.V. Polypeptide variants and uses thereof
MX2019006123A (es) 2016-12-21 2019-08-12 Hoffmann La Roche Metodo para glicomanipulacion in vitro de anticuerpos.
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
MX2019007411A (es) 2016-12-21 2019-08-29 Hoffmann La Roche Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
EP3559248B2 (en) 2016-12-21 2024-11-20 F. Hoffmann-La Roche AG In vitro glycoengineering of antibodies
BR112019015900A2 (pt) 2017-02-10 2020-04-07 Genmab B.V. polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição
US12649798B2 (en) 2018-01-24 2026-06-09 Genmab B.V. Polypeptide variants and uses thereof
EP3774903A1 (en) 2018-04-04 2021-02-17 Bristol-Myers Squibb Company Anti-cd27 antibodies and uses thereof
JP7513530B2 (ja) 2018-06-22 2024-07-09 ジェンマブ ホールディング ビー.ブイ. 抗cd37抗体および抗cd20抗体、組成物、ならびにそれらの使用方法
CN114650829A (zh) * 2019-09-05 2022-06-21 索伦托药业有限公司 结合bcma的二聚体抗原受体(dar)

Similar Documents

Publication Publication Date Title
CA2987118C (en) A pdl-1 antibody, pharmaceutical composition thereof and use thereof
JP6526189B2 (ja) 抗pd−l1抗体並びにその治療及び診断のための使用
CA2932966C (en) Pd-1 antibody, antigen-binding fragment thereof, and medical use thereof
AU2020213579B2 (en) Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
JP2018126157A (ja) 抗cd40抗体および使用方法
JP2020073499A (ja) インターフェロンアルファ及びオメガ抗体アンタゴニスト
JP2016529882A5 (cg-RX-API-DMAC7.html)
JP2008291028A (ja) B細胞リンパ腫および細胞株の処置に効果的な二重特異性抗体
JP2022521723A (ja) クローディン6抗体及びその使用
KR20180021833A (ko) 증진된 효능제 활성을 갖는 cd40에 대한 항체
CN115461370B (zh) St2抗原结合蛋白
CN115894701A (zh) 结合cd3的抗体及其用途
WO2021013142A1 (zh) 抗4-1bb抗体、其抗原结合片段及双特异性抗体
RU2770620C1 (ru) Связывающие молекулы, вызывающие клеточную активацию
JP2024054284A (ja) ガンの処置のための結合分子
TW201235358A (en) Antigen binding proteins
US20250206820A1 (en) Ilt3 and cd3 binding agents and methods of use thereof
JP2024531900A (ja) 新規の抗sirpa抗体
TW202144398A (zh) Cd137結合分子及其用途
JP2022520632A (ja) 共通軽鎖を含む抗体及びその使用
JP2026508244A (ja) 抗Nectin-4抗体及びそれを含む多重特異性抗体
CN111303283A (zh) 抗il-17a抗体及其应用
CA3084398A1 (en) Modified c.kappa. and ch1 domains
RU2816204C2 (ru) Антитело против il-17a и его применение
WO2025126102A1 (en) Enpp3 × cd3 bispecific antibodies and use thereof